Employees
~50
Stage
Commercial
Modalities
Molecular diagnostics

Spear Bio General Information

Developed ultra-sensitive immunoassay platform for protein biomarker detection, received FDA Breakthrough Device Designation for pTau 217 blood test for Alzheimer's diagnosis

Contact Information

Website
Primary Industry
Diagnostics
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Spear Bio's pipeline data

Book a demo

Key Partnerships

Bio-Techne

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Spear Bio Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Spear Bio's complete valuation and funding history, request access »